First dogs, then …

Biotechnology group says treated animals showed improved survival and functional measures in early-stage study

Genflow Biosciences Ltd (LSE: GENF, OTCQB: GENFF, FRA: WQ5) said positive preliminary interim results from its SLAB clinical trial showed improved survival and functional outcomes in aged dogs treated with its proprietary SIRT6 centenarian gene therapy.

The biotechnology company, which focuses on developing gene therapies for age-related diseases, said the randomised, blinded study enrolled 24 beagle dogs aged over 10 years and was conducted by an independent contract research organisation.